Amy Weise

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Lawrence Fong, Andrew Hotson, John D. Powderly et al. · Cancer Discovery · 2019 · 339 citations · Full text

Medicine, Immunology, Oncology +17

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

Geoffrey I. Shapiro, Patricia LoRusso, Afshin Dowlati et al. · British Journal of Cancer · 2020 · 119 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

Aditya Bardia, Virginia Kaklamani, Sharon Wilks et al. · Journal of Clinical Oncology · 2021 · 108 citations · Full text

Medicine, Oncology, Pharmacology +14

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 93 citations · Full text

Medicine, Oncology, Pharmacology +13

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

Mrinal M. Gounder, Todd M. Bauer, Gary K. Schwartz et al. · Journal of Clinical Oncology · 2023 · 91 citations · Full text

Medicine, Oncology, Pharmacology +12